(CercleFinance.com) – Cellectis unveiled yesterday evening the terms of its capital increase project of 20.2 million dollars via the marketing of new American Depositary Shares (ADS).
In a press release, the biotechnology company explains that it plans to offer 8.8 million ADSs, each representing one common share, at a unit price of 2.50 dollars.
The transaction includes a public offering in the United States as well as a private placement with qualified investors in other countries, including Europe.
Of this fundraising, Cellectis plans to use $17 million to finance the continued clinical development of its immunotherapies and the balance to finance its working capital and general needs.
Based on the proceeds envisaged, Cellectis expects to have sufficient cash to finance its activities until the second quarter of 2024.
Listing of Cellectis ordinary shares on Euronext Growth in Paris has been suspended pending the opening this afternoon of ADS trading on the Nasdaq.
It should be noted that the operation will have a dilutive impact of around 16% on existing shareholders, since a 1% stake in the capital before the offer will only correspond to a share of 0.84% after the transaction. .